A Cost Utilization Analysis of Intrathecal Therapy for Refractory Cancer Pain: Identifying Factors Associated with Cost Benefit
Authors:
- Shane E. BroganSBShane E. Brogan
- Annalise AbiodunAAAnnalise Abiodun
- Reza SafarpourRSReza Safarpour
Open Access
- 1 April 2013
- journal article
- Published by Oxford University Press (OUP) in Pain Medicine
- Vol. 14 (4) , 478-486
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Polyanalgesic Consensus Conference 2012: Recommendations for the Management of Pain by Intrathecal (Intraspinal) Drug Delivery: Report of an Interdisciplinary Expert PanelNeuromodulation: Technology at the Neural Interface, 2012
- Patient-Controlled Intrathecal Analgesia for the Management of Breakthrough Cancer Pain: A Retrospective Review and CommentaryPain Medicine, 2011
- Intrathecal Treatment in Cancer Patients Unresponsive to Multiple Trials of Systemic OpioidsThe Clinical Journal of Pain, 2007
- Opioid Conversions in Acute CareAnnals of Pharmacotherapy, 2007
- Alternative Treatments of Breakthrough Pain in Patients Receiving Spinal Analgesics for Cancer PainJournal of Pain and Symptom Management, 2005
- Randomized Clinical Trial of an Implantable Drug Delivery System Compared With Comprehensive Medical Management for Refractory Cancer Pain: Impact on Pain, Drug-Related Toxicity, and SurvivalJournal of Clinical Oncology, 2002
- Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiologyPain, 2001
- Clinical realities and economic considerations: Economics of intrathecal therapyJournal of Pain and Symptom Management, 1997
- Prevalence of symptoms among patients with advanced cancer: An international collaborative studyJournal of Pain and Symptom Management, 1996
- Pain and Its Treatment in Outpatients with Metastatic CancerNew England Journal of Medicine, 1994